publication date: Sep. 4, 2020

In Brief

Patrick Hwu named president and CEO at Moffitt

Tumor immunologist Patrick Hwu was named president and CEO of Moffitt Cancer Center. He will leave his job as the division head of Cancer Medicine at MD Anderson Cancer Center and begin his role at Moffitt Nov. 10.

“I look forward to bringing my years of experience as a cancer physician, researcher and leader to help advance the outstanding work already underway by the teams of cancer experts at Florida’s top-ranked cancer hospital. I’m confident that our collective efforts will further elevate Moffitt’s leadership in cancer patient care, research and education,” Hwu said in a statement.

During his 17 years at MD Anderson, Hwu has served as chair of the Department of Sarcoma Medical Oncology and co-director of the Center for Cancer Immunology Research. He was the first chair of the Department of Melanoma Medical Oncology.

Hwu’s work focuses on vaccines, adoptive T-cell therapies and immune resistance. He helped pioneer the field of gene modified T cells, publishing research on the first chimeric antigen receptor directed against cancer. He is the principal investigator on an NCI SPORE grant for melanoma.

Hwu replaces Alan List, former president and CEO, who stepped down Dec. 18, 2019, after an internal review alleged that he and Moffitt Director and Executive Vice President Thomas Sellers had violated “conflict of interest rules through their work in China.”  Sellers was replaced by John L. Cleveland (The Cancer Letter, Jan. 3, Feb. 14, March 6, May 29, 2020).

Hwu is vice president/president elect at the Society for Immunotherapy of Cancer, serves on the Melanoma Research … Continue reading Patrick Hwu named president and CEO at Moffitt

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.